Results 21 to 30 of about 33,409 (329)

In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO)

Scientific Reports, 2021
Data of thoracic in-field reirradiation with two courses of stereotactic body radiotherapy (SBRT) is scarce. Aim of this study is to investigate feasibility and safety of this approach.
Caroline John, R. Dal Bello, N. Andratschke, M. Guckenberger, J. Boda-Heggemann, E. Gkika, F. Mantel, H. Specht, C. Stromberger, F. Zehentmayr, O. Blanck, P. Balermpas   +11 more
semanticscholar   +1 more source

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges

Journal of Hematology & Oncology, 2020
Immune checkpoint inhibitors targeting programmed cell death 1 (PD-1), programmed cell death ligand-1 (PD-L1), and others have shown potent clinical efficacy and have revolutionized the treatment protocols of a broad spectrum of tumor types, especially ...
Yu Chen, M. Gao, Zhaoqin Huang, Jinming Yu, Xiangjiao Meng   +4 more
semanticscholar   +1 more source

1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment

Radiation Oncology, 2020
Unity Elekta is a unique magnetic resonance (MR)-linac that conjugates a 1.5 Tesla MR unit with a 7 MV flattening filter free accelerator.A prospective observational study for the clinical use of Elekta Unity is currently ongoing in our department ...
F. Alongi, M. Rigo, V. Figlia, F. Cuccia, N. Giaj-Levra, L. Nicosia, F. Ricchetti, G. Sicignano, A. Simone, S. Naccarato, R. Ruggieri, R. Mazzola   +11 more
semanticscholar   +1 more source

Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021
INTRODUCTION Preclinical evidence demonstrates the immunogenic potential of stereotactic body radiotherapy (SBRT). There is growing interest in investigating this interplay with the immune system in metastatic renal cell carcinoma (mRCC).
J. Peng, Aly-Khan A. Lalani, A. Swaminath   +2 more
semanticscholar   +1 more source

AAPM-RSS Medical Physics Practice Guideline 9.b: SRS-SBRT. [PDF]

J Appl Clin Med Phys
Abstract The purpose of this Medical Physics Practice Guideline (MPPG) is to describe the minimum level of medical physics support deemed prudent for the practice of linear‐accelerator, photon‐based (linac) stereotactic radiosurgery (SRS), and stereotactic body radiation therapy (SBRT) services.
Cirino E, Benedict SH, Dupre PJ, Halvorsen PH, Kim GG, Reyhan ML, Schneider CW, Wang L, Weaver CP, Yoo S.   +9 more
europepmc   +2 more sources

Current Understanding of Ablative Radiation Therapy in Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma, 2021
Ashwathy S Mathew,1 Laura A Dawson2,3 1Department of Radiation Oncology, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India; 2Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; 3Department of Radiation Oncology ...
Mathew AS, Dawson LA
doaj  

Evaluation of spine structure stability at different locations during SBRT

Biomedical Papers, 2020
Background and Aims: Modern stereotactic body radiotherapy (SBRT) techniques and systems that use online image guidance offer frameless radiotherapy of spinal tumors and the ability to control intrafraction motion during treatment.
Lukas Knybel, Jakub Cvek, Zuzana Cermakova, Jaroslav Havelka, Michaela Pomaki, Kamila Resova   +5 more
doaj   +1 more source

Impact of Stereotactic Body Radiotherapy on Thrombin Generation and Platelet Aggregation in Patients with Non-Small Cell Lung Cancer

Clinical and Applied Thrombosis/Hemostasis, 2023
Patients with localized non-small cell lung cancer (NSCLC) considered unfit for surgery are at substantially increased risk of venous thromboembolism. Radiotherapy may further increase this risk.
Kristian Kirkelund Bentsen MD, Johanne Andersen Hojbjerg MD, PhD, Pernille Just Vinholt MD, PhD, Olfred Hansen MD, PhD, Anne-Mette Hvas MD, PhD, Stefan Starup Jeppesen MD, PhD   +5 more
doaj   +1 more source

Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-alone in Unresectable Hepatocellular Carcinoma (HCC)

Liver Cancer, 2023
Introduction While combination of stereotactic body radiotherapy (SBRT) and immunotherapy are promising, their efficacy and safety have not been compared with SBRT-alone in patients with unresectable HCC.
Chi Leung Chiang, Francis Ann Shing Lee, Kenneth Sik Kwan Chan, Venus Wan Yan Lee, Keith Wan Hang Chiu, Ryan Lok Man Ho, John Ka Shun Fong, Natalie Sean Man Wong, Winnie Wing Ling Yip, Cynthia Sin Yu Yeung, Vince Wing Hang Lau, Kwan Man, Feng-Ming Spring Kong, Albert Chi Yan Chan   +13 more
doaj   +1 more source

Best practices in surgical and nonsurgical management of head and neck Merkel cell carcinoma: An update

Molecular Carcinogenesis, Volume 62, Issue 1, Page 101-112, January 2023., 2023
Abstract Merkel cell carcinoma (MCC) is a rare, highly aggressive cutaneous neuroendocrine carcinoma. Controversy exists regarding optimal management of MCC as high‐quality randomized studies and clinical trials are limited, and physicians are bound to interpret highly heterogeneous, retrospective literature in their clinical practice. Furthermore, the
Daniela Duarte‐Bateman, Alan Shen, Taylor Bullock, Payam Sadeghi, Joseph M. Escandón, Eliska Dedkova, Brian R. Gastman   +6 more
wiley   +1 more source